Journal of Clinical Oncology
Articles in this Issue
An extracellular vesicle-based assay for early detection of pancreatic ductal adenocarcinoma.
e16463 Background: Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, primarily due to its late-stage diagnosis. This study focuses o...
Strengthening multidisciplinary collaboration to enhance early-stage melanoma outcomes: A quality improvement initiative.
e21574 Background: Guideline recommendations for adjuvant systemic treatment in stages II or III cutaneous melanoma include assessment for immunotherapy (...
Identifying and addressing barriers to germline testing in ovarian cancer.
e17554 Title: Identifying and addressing barriers to germline testing in ovarian cancer Background: Ovarian cancer is the fifth le...
Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database.
e13145 Background: Sacituzumab Govitecan (SG) a Trop2-targeted antibody-drug conjugate (ADC) was reported to cause neutropenia among 63% patients in clini...
Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.
5014 Background: Metastasis directed therapy (MDT) with stereotactic body radiotherapy (SBRT) is a standard of care in patients with oligometastatic hormo...
CUPID ( <sup>64</sup> Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592 targeted alpha therapy in prostate cancer.
e17023 Background: Antibody-based PSMA-targeting therapies have potential to overcome limitations of small molecule approaches such as undesirable off-tar...
Regional trends in incidence and prevalence of gastric cancer among older adults (70+) from 1990 to 2021: A global burden of disease study.
e16481 Background: Gastric cancer is a malignant disease characterized by the uncontrolled growth of cells in the stomach lining. It is a global health co...
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
TPS3634 Background: For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver,...
Dynamic changes in circulating tumor DNA among Taiwanese early breast cancer patients undergoing upfront surgery: Results from the VGH-TAYLOR study.
558 Background: Circulating tumor DNA (ctDNA) has emerged as a promising prognostic marker in breast cancer. Post-treatment ctDNA detection is associated...
A multidisciplinary approach for treatment choice in cancer patients with cardiovascular diseases: Experience of a large municipal hospital.
e24022 Background: Cancer and cardiovascular diseases (CVD) competitive risks have to be evaluated during the choice of cancer treatment. Meth...
Survival analysis based on markers of progression in melanoma: A single-center comparison of survival in patients with high vs low biomarkers.
e21573 Background: In melanoma, biomarkers such as lactate dehydrogenase (LDH), circulating tumor DNA (ctDNA), and the neutrophil-lymphocyte ratio (NLR) h...
Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test.
5582 Background: The high mortality of Ovarian cancer (OC) has been attributed to late-stage diagnosis and the lack of an effective early detection strate...
Ethnic disparities in unmet supportive care needs and outcomes among older ambulatory cancer patients.
11108 Background: Older cancer patients often face unmet supportive care needs (USCNs), leading to adverse clinical outcomes. Existing research largely fo...
Cancer patients' messages about radiology/pathology reports: Insights for AI.
1570 Background: Cancer patients often use portals to view results prior to discussing with physicians, leading to messages with questions or concerns....
A retrospective study of induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy in unresectable locally advanced non-small cell lung cancer.
8076 Background: The standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC) involves concurrent chemoradiotherapy...
Development and validation of a proteo-metabolic panel for detection of asymptomatic ovarian cancer with minimal serum sample requirements: A multi-center prospective study.
5546 Background: Early diagnosis is crucial for improving the prognosis of ovarian cancer (OC). However, most patients (pts) are diagnosed at advanced sta...
Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
1070 Background: Progression of ER+/HER2- mBC on 1L endocrine therapy (ET) + CDK4/6i is associated with several mechanisms of resistance that impact effic...
Neoadjuvant IBI110 and sintilimab in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma.
e18092 Background: Lymphocyte-activation gene 3 (LAG-3) has emerged as a novel target for immunotherapy. Herein, we reported a phase Ib trial to investiga...
ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.
TPS7085 Background: R-CHOP as 1L therapy for LBCL has a cure rate of ~60%. However, ~10% of pts are refractory (Coiffier, NEJM 200...
Predicting survival outcomes in pancreatic mucinous adenocarcinoma (PMA) using machine learning.
e16430 Background: PMA accounts for 3% of pancreatic ductal adenocarcinomas and remains understudied, often leading to challenging management. We aimed to...
A single-center experience of chemotherapy combined with radiofrequency ablation and immunotherapy in patients with locally advanced/metastatic pancreatic ductal adenocarcinoma.
e16413 Background: Standard of care (SOC) chemotherapy with either FOLFIRINOX or gemcitabine/nab-paclitaxel provides an overall response rate (ORR) < 3...
A new option for post-CDK4/6is resistance era? Multicenter real-world study of anlotinib-based combination therapy in hormone receptor-positive metastatic breast cancer resistant to CDK4/6 inhibitors.
e13059 Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors (CDK4/6is) combined with hormonal therapy are the current standard frontline treat...
Efficacy and safety of tyrosine kinase inhibitors and low dose immunotherapy in metastatic renal cell carcinoma.
e16518 Background: The Phase-III Checkmate 9ER trial has established cabozantinib and nivolumab as an approved first-line treatment option in patients wit...
Thromboembolic disease in breast cancer: Analysis of risk factors and outcomes from the 2022 National Inpatient Sample and Readmission database.
e23339 Background: Thromboembolic disease significantly impacts breast cancer patients' outcomes and healthcare resource utilization. We analyzed the 2022...
Concordance analysis between tumor tissue HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH) and a translational analysis of plasma ctDNA in patients (pts) with biliary tract cancer (BTC): An exploratory analysis from the phase 2 HERIZON-BTC-01 trial.
4102 Background: HER2 is a target for precision oncology. HER2 protein overexpression and/or gene amplification is observed in a subset of pts with BTC. Z...